RadNet, Inc. reports recurring developments in outpatient diagnostic imaging, digital health, and radiology technology. The company operates owned and managed imaging centers that provide MRI, CT, PET/CT, mammography, ultrasound, X-ray, fluoroscopy, nuclear medicine, and related procedures for physicians and patients across U.S. markets.
RadNet news commonly covers financial results, imaging-center procedure volumes, guidance updates, joint ventures, acquisitions, and customer or technology collaborations. Its Digital Health segment includes DeepHealth, which provides radiology information technology, AI-powered health informatics, clinical AI applications, patient engagement tools, operational AI, teleradiology services, and related products for the diagnostic imaging industry.
RadNet (NASDAQ: RDNT) has announced the acquisition of iCAD (NASDAQ: ICAD) in an all-stock transaction valued at approximately $103 million. Under the agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each iCAD share, representing $3.61 per share and a 98% premium based on April 14, 2025 closing prices.
The merger combines iCAD's ProFound Breast Health Suite with RadNet's DeepHealth AI-powered breast screening solutions. iCAD's network spans over 1,500 healthcare provider locations across 50 countries, facilitating over 8 million annual mammograms. The integration aims to enhance breast cancer detection accuracy and early diagnosis capabilities.
The transaction, unanimously approved by both companies' boards, is expected to close in Q2 or Q3 2025, subject to iCAD stockholder approval and customary closing conditions.
RadNet (NASDAQ: RDNT), a national leader in diagnostic imaging services, has announced its participation in the upcoming 35th Annual Oppenheimer Healthcare MedTech & Services Conference. The company's Executive Vice President and Chief Executive Officer, Mark Stolper, will deliver a virtual presentation on March 17, 2025, at 12:40 p.m. Eastern Time.
The presentation will be accessible through a live webcast at wsw.com/webcast/oppenheimer40/rdnt/2795776, with replay options available. RadNet operates a network of fully-owned and operated outpatient imaging centers, focusing on providing high-quality, cost-effective diagnostic imaging services.
RadNet (NASDAQ: RDNT) reported strong Q4 2024 financial results with record-breaking performance. Total revenue increased 13.5% to $477.1 million, while Adjusted EBITDA grew 14.0% to $75.0 million compared to Q4 2023. The Digital Health segment showed impressive growth with revenue up 28.1% to $18.9 million.
Key operational highlights include:
- 8.0% increase in aggregate procedural volumes
- 4.0% growth in same-center procedural volumes
- Strong imaging volume growth: MRI +13.4%, CT +13.9%, PET/CT +23.9%
- Expansion to 398 imaging centers, with 38.4% being joint venture facilities
The company maintained a strong financial position with $740 million cash balance and net debt to Adjusted EBITDA ratio under 1.0x. Adjusted Earnings Per Share reached $0.22 in Q4 2024, up from $0.15 in Q4 2023.
RadNet (NASDAQ: RDNT) has announced a strategic partnership with OB/GYN Specialists of the Palm Beaches to launch breast imaging services across multiple locations in Palm Beach County. The collaboration integrates RadNet's DeepHealth AI-powered diagnostic solutions with OB/GYN Specialists, the largest obstetric and gynecological care provider in the region serving 60,000 women annually across 10 locations.
The partnership features RadNet's Enhanced Breast Cancer Detection (EBCD) protocol, which has demonstrated a 21% increase in breast cancer detection rates. The service includes interpretation by RadNet's board-certified breast imaging radiologists and implements DeepHealth's AI-driven health informatics, featuring cloud-based operating systems, patient tracking, and risk assessment integrated with EHR systems.
DeepHealth, a subsidiary of RadNet (NASDAQ: RDNT), will showcase new AI-powered radiology solutions at ECR 2025 in Vienna. The company will introduce Diagnostic Suite™, a cloud-native PACS alternative, and SmartMammo™, an AI-powered mammography solution that has shown a 21% increase in cancer detection rate.
The company's AI-powered Lung solution is currently supporting the NHS England's Lung Cancer Screening Program, where 76% of cancers were detected at earlier stages, compared to 29% historically. Their Prostate solution has demonstrated 97% diagnostic sensitivity and 37% reduction in workflow time for MRI reads.
DeepHealth's solutions are powered by DeepHealth OS, a cloud-native operating system integrating data across various platforms. The company's technology is currently utilized by over 800 clinical sites and more than 3,000 radiologists globally.
RadNet's subsidiary DeepHealth and ConcertAI's TeraRecon announced a strategic collaboration to advance imaging tools and radiology workflow. The partnership will integrate TeraRecon's advanced visualization technology into DeepHealth OS cloud-native Operating System, while incorporating DeepHealth's clinical AI solutions into TeraRecon's AI ecosystem.
The collaboration aims to create a seamless AI-enabled diagnostic experience for radiologists through DeepHealth's Diagnostic Suite™, enhancing diagnostic accuracy and efficiency. As imaging volumes rise, these integrated AI-powered solutions will help radiology departments manage workload while maintaining precision.
Both companies will explore additional areas to integrate AI-driven imaging and workflow automation, potentially including DeepHealth's AI-powered cancer screening capabilities in TeraRecon's ecosystem. The partnership will be showcased at the European Congress of Radiology 2025 in Vienna from February 26 to March 2.
RadNet (NASDAQ: RDNT), a national leader in diagnostic imaging services, has scheduled its fourth quarter 2024 financial results conference call for Friday, February 28, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors can participate by dialing 844-826-3035 (US) or 412-317-5195 (International). The company will provide simultaneous and archived webcasts of the call, accessible through their dedicated webcast platform. An archived replay will be available via phone using the passcode 10197109.
RadNet (NASDAQ: RDNT), a leading provider of outpatient diagnostic imaging services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Wednesday, January 15th, 2025, at 3:00 p.m. PST at The Westin St. Francis Hotel.
Key executives participating in the presentation include Dr. Howard Berger (President and CEO), Mark Stolper (EVP and CFO), and Dr. Gregory Sorensen (EVP and Chief Science Officer). The presentation will be available via live webcast and can be accessed through the provided link for replay viewing.
DeepHealth, a subsidiary of RadNet (RDNT), has chosen Ketryx to accelerate its AI-powered health informatics solutions development. The partnership aims to streamline radiology workflows and enhance care delivery through DeepHealth's cloud-native operating system. According to FDA data, 79% of newly approved devices in radiology utilize AI/ML technologies.
DeepHealth will leverage Ketryx's connected lifecycle management software to accelerate product development while maintaining quality and compliance. The integration with tools like Jira and GitLab enables automated documentation and end-to-end traceability, helping expedite innovative product releases while adhering to regulatory requirements.
RadNet (NASDAQ: RDNT), a leading provider of diagnostic imaging services, has announced its participation in the BofA Securities 2024 Leveraged Finance Conference. Mark Stolper, Executive Vice President and CFO, will present at the conference in Boca Raton, FL on December 3, 2024, at 8:10 a.m. Eastern Time (5:10 a.m. Pacific Time).
The presentation will be accessible through simultaneous and archived webcasts available on both the BofA conference platform and RadNet's corporate website under the 'About RadNet' section and 'News and Press Releases' sub-menu.